MSAC Standards of Care Subcommittee

Victoria P. Werth, MD   Victoria P. Werth, MD, Chair
Professor of Dermatology & Medicine
University of Pennsylvania,
School of Medicine
Philadelphia, PA
Karen H. Costenbader, MD, MPH   Karen H. Costenbader, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Brigham and Women’s Hospital
Boston, MA
Andrew G. Franks, Jr. MD   Andrew G. Franks, Jr., MD
Professor of Clinical Dermatology
New York University School of Medicine
New York, NY
Richard Furie, MD   Richard Furie, MD
Chief, Division of Rheumatology and Allergy-Clinical Immunology
North Shore-LIJ Health System
Lake Success, NY
Bevra H. Hahn, MD   Bevra H. Hahn, MD
Professor Emeritus
University of California, Los Angeles School of Medicine
Los Angeles, CA
Kenneth C. Kalunian, MD   Kenneth C. Kalunian, MD
Associate Director of the Center for Innovative Therapy
Professor of Clinical Medicine
Div. of Rheumatology, Allergy and Immunology
University of California at San Diego School of Medicine
La Jolla, CA
Diane L. Kamen, MD, MSCR   Diane L. Kamen, MD, MSCR
Associate Professor of Medicine
Medical University of South Carolina
Charleston, SC
Mimi Kim, ScD   Mimi Kim, ScD
Professor and Head, Division of Biostatistics
Albert Einstein College of Medicine of Yeshiva University
Bronx, NY
Timothy B. Niewold, MD   Timothy B. Niewold, MD
Associate Professor
The Mayo Clinic
Rochester, MN
Brad H. Rovin, MD   Brad H. Rovin, MD
Professor of Medicine and Pathology
Director, Division of Nephrology
Director, Fellowship Program in Nephrology
The Ohio State University College of Medicine
Columbus, OH
Laura R. Schanberg, MD   Laura E. Schanberg, MD
Professor of Pediatrics
Duke University Medical Center
Durham, NC
Emily von Scheven, MD   Emily von Scheven, MD
Director, Pediatric Rheumatology Clinic
University of California, San Francisco
Benioff Children's Hospital
San Francisco, CA

Because there has only been one drug approved specifically for lupus in the past 50 years, health care providers must rely on off-label use of medications approved for other indications (some of them being highly toxic and presenting a host of adverse side effects). Since there are no formal or standardized disease management guidelines or treatment protocols for lupus, and because each patient presents differently, physicians are essentially using case-by case investigational methods to determine the most appropriate treatments for their patients.